The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality

Minke H. T. Hartman*, Ruben N. Eppinga, Pieter J. J. Vlaar, Chris P. H. Lexis, Erik Lipsic, Joost D. E. Haeck, Dirk J. van Veldhuisen, Iwan C. C. van der Horst, Pim van der Harst

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: ArticleAcademicpeer review

15 Citaten (Scopus)


BackgroundComplex multimarker approaches to predict outcome after ST-elevation myocardial infarction (STEMI) have only considered a single baseline sample, while neglecting easily obtainable peak creatine kinase and creatine kinase-MB (CK-MB) values during hospitalization.

MethodsWe studied 476 patients undergoing primary percutaneous coronary intervention for STEMI and cardiac magnetic resonance imaging (CMRI) at 4-6 months after STEMI. We determined the association with cardiac biomarkers (peak CK-MB, peak troponin T, N-terminal pro-brain natriuretic peptide), clinical and angiographic characteristics with infarct size, and LVEF, followed by association with mortality in 1120 STEMI patients.

ResultsPeak CK-MB was the strongest predictor for infarct size (P

ConclusionsClassical peak CK-MB measured during hospitalization for STEMI was superior to other clinical and angiographic characteristics in predicting CMRI-defined infarct size and LVEF, and should be included and validated in future multimarker studies. Peak CK-MB cutpoints differentiated among infarct size categories and were associated with increased 90-day mortality risk.

Originele taal-2English
Pagina's (van-tot)322-328
Aantal pagina's7
TijdschriftClinical Cardiology
Nummer van het tijdschrift5
StatusPublished - mei-2017

Citeer dit